Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment.

The pharmacogenomics journal - 1 Dec 2008

Heitjan D F, Asch D A, Ray Riju, Rukstalis Margaret, Patterson Freda, Lerman C

Abstract excerpt

We evaluated the cost-effectiveness of a range of smoking cessation drug treatments, including varenicline, transdermal nicotine (TN), bupropion and the use of a genetic test to choose between TN and bupropion. We performed Monte Carlo simulation with sensitivity analysis, informing analyses with published estimates of model parameters and current prices for genetic testing and smoking-cessation therapy. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzazepines
Share to Bupropion
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Pharmacogenetics

Share to Quinoxalines

Share to Receptors, Nicotinic

Share to Smoking Cessation

Source

Open in PubMed Open full text

Identifiers

PMID: 18347612
DOI: 10.1038/sj.tpj.6500492
PMCID: PMC5618442

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment.PMID 18347612Read ↗

A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation.Semantic proximity Read ↗

Pharmacogenetics and nicotine addiction treatment.Semantic proximity Read ↗

Pharmacogenetic Optimization of Smoking Cessation Treatment.Semantic proximity Read ↗

Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.Semantic proximity Read ↗

Smoking cessation treatment: pharmacogenetic assessment.Semantic proximity Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Helping smokers quit through pharmacogenetics.Semantic proximity Read ↗

Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?Semantic proximity Read ↗

Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolismSemantic proximity Read ↗

Pharmacogenetics of smoking cessation therapySemantic proximity Read ↗

A research agenda for assessing the potential contribution of genomic medicine to tobacco control.Semantic proximity Read ↗

What's needed for personalized therapy in smoking cessation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.